FDA Patient-Focused Drug Development Guidance Series for Enhancing the Incorporation of the Patient’s Voice in Medical Product Development and Regulatory Decision Making

Patient-Focused Drug Development

FDA is developing a series of four methodological patient-focused drug development (PFDD) guidance documents to address, in a stepwise manner, how stakeholders can collect and submit patient experience data and other relevant information from patients and caregivers for medical product development and regulatory decision making. This series of guidance documents is intended to facilitate the advancement and use of systematic approaches to collect and use robust and meaningful patient and caregiver input that can better inform medical product development and regulatory decision making.

These guidances are part of FDA’s PFDD efforts in accordance with the 21st Century Cures Act and The Food and Drug Administration Reauthorization Act of 2017 Title I.

This webpage contains information and documents related to FDA’s development of the methodological PFDD guidances, including public workshops, draft guidances, and hypothetical scenarios, which are all intended to serve as a basis for dialogue. For an outline of FDA’s planned timeframe for development of the guidance, please refer to the Plan for Issuance of Patient-Focused Drug Development Guidance.

Guidance 1 will discuss sampling methods that could be used when planning to collect patient input. It will also provide a general overview of the relationship between potential research question(s) and method(s) when deciding from whom to get input (including defining the target population and development of the sampling strategy).

Guidance 2 will discuss methods for eliciting information from individuals identified in Guidance 1, gathering information about what aspects of symptoms, impacts of their disease, and other issues are important to patients. It will discuss best practices in how to do qualitative research including conducting interviews, development of interview guides, selection of types of survey questions, and considerations for collecting demographics and survey information. It will also discuss survey methods and qualitative research topics to help avoid misleading results such as inadvertently priming patients in ways that can lead to results that poorly represent what is important to patients.

Guidance 3 will address refining the list of important impacts and concepts from patients to develop potential study instruments. Given that not everything identified as important by patients, caregivers, and clinicians can demonstrate change in a specific treatment trial or is measurable, how will you select what to measure in a medical product development program to show clinical benefit? How will you identify or develop fit-for-purpose COAs to assess outcomes of importance to patients?

Guidance 4 will address topics related to COA-related endpoint development and interpretation, including topics related to instrument administration and meaningful within-patient score changes.

Back to CDER Patient-Focused Drug Development

More in Development & Approval Process (Drugs)

Clinical Data Summary Pilot Program Drug Development Tool Qualification Programs Guidance Documents for Drug Applications Laws, Regulations, Policies and Procedures for Drug Applications

Page Last Updated: 06/29/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English